Skip to main content
OpenTrials
Completed

NCT Number: NCT04724629

Survival TRial Using CytoKines in COVID-19 (STRUCK Trial)

Currently, there are few approved treatments for COVID-19, antiretroviral (remdesivir) and corticoids. With about 15% of COVID-19 patients suffering from severe disease health system will be overwhelmed. Treatments approaches to inhibit viral replication (antiretroviral and extended spectrum antiviral drugs), such as Remdesivir and Hydroxychloroquine are being used. In severe cases, by CT scans investigators are able to observe that these patients seem to be dying with fibrosis and lung vasculitis. It is hypothesised that targeting vasculitis and lung inflammation secondary to the viral infection may help patients' survival (reducing mortality) and/or decrease time in mechanical ventilators. It is proposed a 4-arm trial, converted to 2 after interim analysis (60 patients for the initial phase, sample size recalculation after initial analysis and 2 arms beyond). In initial phase, IL-6 indirect inhibitor (colchicine), in first arm; IL-17 inhibitor, an innovative target never tested (at this moment) in COVID-19 severe patients, in second study arm. Both approaches (indirect IL-6 and Il-17) are related to modulation of inflammatory immune response. Finally, in third arm, IL-2 low dose. This cytokine was identified as Treg upregulation. Treg levels decrease in hepatitis C virus (HCV) associated vasculitis and increase in vasculitis resolution. In fourth arm, control group, standard of care. Initially, for the first 60 included patients, the study will comprise 4 arms (15 patients per arm, randomization ratio 1:1:1:1). An interim effectiveness and safety analysis at this point will guide the selection of one single treatment strategy (adaptative study) to be carried on after that, comparatively with the control group. The multi-site trial planned enrollment duration of 4-6 months and for each participant will be approximately 4 weeks. This trial will bring complementary data to the global effort in COVID-19 cases resolution.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Faculdade de Medicina de Ribeirão Preto - USP, Ribeirão Preto, São Paulo, Brazil

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Positive result in the quantitative real-time PCR (qPCR) test for SARS-CoV-2 in the respiratory tract;
  • Pneumonia confirmed by chest imaging and
  • Respiratory rate ≥ 24 IRPM (for adults) or
  • O2 saturation <93% or
  • No improvement in O2 saturation, despite oxygen supply or
  • Arterial hypotension; or
  • Changes in capillary filling time; or
  • Changes in the level of consciousness; or
  • Oliguria;

IMPORTANT: The presence of increased respiratory rate or desaturation (items "a" and "b") are criteria for hospital admission. Items "c" to "g" are considered criteria for ICU admission

Following the recommendations of The São Paulo State Health Secretariat, resolution SS-28 of 03-Mar-2020, prepared by the Hospital das Clínicas of Medical School-USP.

Exclusion criteria

  • Age <18 years;
  • Refuse to sign the Informed Consent Form;
  • Patient's decision that their involvement is not in their interest;
  • Severe known liver disease (eg cirrhosis, with aminotransferase levels> 5 times the reference value limit);
  • Pregnancy or breastfeeding period;
  • Severe bacterial infection;
  • Severe diarrhea;
  • Diverticulitis or intestinal perforation;
  • Infection known as HIV;
  • Presence of one of the following uncontrolled or unstable cardiovascular diseases: stroke, ECG confirmed acute ischemia or myocardial infarction and / or clinically significant dysrhythmia; • Known history of gastrointestinal bleeding, uncontrolled peptic ulcer or uncontrolled duodenal ulcer;
  • Known history of hemophilia or other bleeding disorders;
  • History of organ transplantation, congenital immunodeficiency;

Treatment and study plan

Ixekizumab

Biological

80 mg of IL-17 inhibitor

Other names: Taltz

aldesleukin

Biological

1.5 million IU (low-dose) of IL-2

Other names: Proleukin

Colchicine

Drug

0.5 mg of indirect IL-6 inhibitor

Standard of Care (SOC)

Drug

Active comparator (Corticoids and antiretrovirals)

Primary outcomes

  1. Ordinal scale of seven World Health Organization (WHO) categories of IL-17 inhibitor versus low dose IL-2 versus indirect IL-6 inhibitor (colchicine) versus standard treatment in the treatment of severe COVID-19

    Time frame: On the 21st day of study, since inclusion.

    proportion of patients with clinical improvement, defined by an increase of two points in the ordinal scale of seven WHO categories

Secondary outcomes

  1. Time until independence from oxygen therapy in days

    Time frame: During the follow-up period (30 days (+/- 2))

  2. Ventilator free days (in days)

    Time frame: During the follow-up period (30 days (+/- 2))

  3. Assessment of worsening pulmonary involvement, defined as the presence of one of these criteria (absence or presence)

    Time frame: At some point in Day 7, Day 14 and Day 28

    Need to increase the inspired fraction of O2 (FIO2) to keep oxygen saturation stable or the need for mechanical ventilation; b. Increase in the number and / or extension of affected lung areas on chest computed tomography.

  4. In patients who needed mechanical ventilation, time to indicate mechanical ventilation

    Time frame: Day 0 up to 45 days

    (calculated in days, from entry into the protocol until orotracheal intubation, up to 45 days)

  5. Duration of hospitalization, in survivors

    Time frame: On day 28

    In days

  6. Analysis of in-hospital mortality

    Time frame: Day 0 up to 45 days

  7. Analysis of general mortality

    Time frame: During the follow-up period (30 days (+/- 2))

Other outcomes

  1. Correlation among the inflammatory proteins D-dimer, C- reactive protein (CRP), Lactate Dehydrogenase (LDH) Test, and ferritin with:

    Time frame: During the follow-up period (30 days (+/- 2))

    7 points WHO original scale; b. Time until independence from oxygen therapy; c. Need for mechanical ventilation; d. Days free of mechanical ventilation; e. Mortality

  2. Changes from baseline of cytokine storm surrogate markers: white blood counts, lymphocyte counts, neutrophils counts, C-Reactive protein (CRP), ferritin (if applicable), D-dimer (if applicable)

    Time frame: at Day 0, Day 2, Day 4, Day 7, Day 14, Day 21 and Day 28 after randomization;

    Changes from baseline of cytokine storm surrogate markers: white blood counts, lymphocyte counts, neutrophils counts, CRP, ferritin (if applicable), D-dimer (if applicable)

  3. Change in Score for Sepsis (SOFA score)

    Time frame: On days 7 and 14 of randomization

  4. Analysis of secondary infections

    Time frame: During the follow-up period (30 days (+/- 2))

  5. Qualitative and quantitative assessment of treatment- related adverse effects assessed by the Common Terminology Criteria for Adverse Event (CTCAE) version 5.0.

    Time frame: Within the first month

Sponsors and collaborators

Lead sponsor

University of Sao Paulo

Other

Collaborators

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Science Valley Research Institute

Registry information

Official study title

Prospective-randomized Adaptive Study, With Active Control to Evaluate the Efficacy and Safety of Interleukin (IL)-17 Inhibitor Treatment Versus Low Doses of IL-2 Versus Indirect IL-6 Inhibitor in Hospitalized Patients With Severe Forms of COVID-19

Acronym: STRUCK

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Jan 26, 2021
Registry last updated
Jul 28, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.